Keros Therapeutics, Inc.
NasdaqGM:KROS Rapporto sulle azioni
Keros Therapeutics Crescita futura
Future criteri di controllo 2/6 Si prevede che Keros Therapeutics aumenterà gli utili e i ricavi rispettivamente del 0.4% e 79.7% all'anno, mentre si prevede che l'EPS crescerà del 7.4% all'anno.
Informazioni chiave
0.4%
Tasso di crescita degli utili
7.4%
Tasso di crescita dell'EPS
Biotechs crescita degli utili 27.3% Tasso di crescita dei ricavi 79.7% Rendimento futuro del capitale proprio n/a Copertura analitica Good
Ultimo aggiornamento 11 Nov 2024
Aggiornamenti recenti sulla crescita futura
Price target increased by 7.1% to US$88.11 Mar 12
Price target decreased by 9.3% to US$81.89 Dec 12
Consensus forecasts updated Dec 12
Consensus EPS estimates fall by 18% May 11
Price target increased to US$98.75 Oct 03
Price target increased to US$94.00 Sep 12
Mostra tutti gli aggiornamenti
Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial Sep 03
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation Aug 07
Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association Jun 19
Keros Therapeutics, Inc. Announces Leadership Updates Jun 18
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers Jun 10
Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024 May 29
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%? Apr 23
Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024 Apr 19
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes Mar 15
Price target increased by 7.1% to US$88.11 Mar 12
New major risk - Revenue and earnings growth Mar 01
Chief Financial Officer notifies of intention to sell stock Jan 07 Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million. Jan 05
Insufficient new directors Jan 01
Price target decreased by 9.3% to US$81.89 Dec 12
Consensus forecasts updated Dec 12
Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition Dec 11
Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society Oct 06
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely Sep 24
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index Jun 25
Chief Financial Officer notifies of intention to sell stock Jun 12
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth Jun 10
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association Jun 10
Consensus EPS estimates fall by 18% May 11
Insufficient new directors Apr 02
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth Dec 25 Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)
Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012 Nov 09
Price target increased to US$98.75 Oct 03
Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting Sep 13
Price target increased to US$94.00 Sep 12
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth Sep 08
Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07 Aug 04
Chief Scientific Officer exercised options and sold US$57k worth of stock Jul 16
Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions Jun 14
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association Jun 11
Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers May 19
Price target increased to US$93.75 May 18 Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
Chief Scientific Officer exercised options and sold US$220k worth of stock May 14
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth Apr 29
Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022 Apr 19
Chief Scientific Officer exercised options and sold US$475k worth of stock Apr 07
Chief Scientific Officer exercised options and sold US$141k worth of stock Mar 17
Chief Scientific Officer exercised options and sold US$137k worth of stock Feb 16
Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer Feb 01
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely Jan 24
Chief Scientific Officer exercised options and sold US$158k worth of stock Jan 09
Chief Scientific Officer exercised options and sold US$133k worth of stock Dec 16
Keros Therapeutics, Inc. Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition Dec 15
Chief Scientific Officer exercised options and sold US$527k worth of stock Nov 06
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth Oct 10
Consultant Claudia Ordonez has left the company Sep 19 Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Microcap Value Index
Keros Therapeutics, Inc. Announces Preliminary Results from Its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes Jun 24
Chief Scientific Officer notifies of intention to sell stock Jun 17
Keros Therapeutics, Inc. Presents Data from the ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress Jun 12
Keros Therapeutics, Inc. Announces Results from A Preclinical Study of KER-012 May 15
Chief Scientific Officer exercised options and sold US$132k worth of stock May 14
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely May 05
Chief Scientific Officer exercised options and sold US$316k worth of stock Apr 16
Chief Scientific Officer exercised options and sold US$340k worth of stock Mar 16
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock? Mar 13
Keros Therapeutics, Inc. Announces Results from Preclinical Studies of KER-050 and ALK2 Inhibitor Program Mar 07
New 90-day low: US$55.25 Mar 05
Chief Scientific Officer notifies of intention to sell stock Feb 17
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate Jan 19
Keros Therapeutics, Inc. Announces Board Changes Dec 19
New 90-day high: US$79.96 Dec 09
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares? Nov 27
New 90-day high: US$68.02 Nov 17
Keros Therapeutics prices equity offering at $50 Nov 13
Keros Therapeutics, Inc. Receives Notice of Termination of the Collaboration Agreement from Novo Nordisk A/S Nov 11
New 90-day high: US$63.21 Oct 29 Keros Therapeutics, Inc. has completed an IPO in the amount of $96 million.
Analysts update estimates Aug 20
New 90-day high - US$40.63 Aug 19
First half earnings released Aug 14
Previsioni di crescita degli utili e dei ricavi NasdaqGM:KROS - Stime future degli analisti e dati finanziari passati (USD Millions ) Data Ricavi Guadagni Flusso di cassa libero Liquidità dell'operazione Avg. Numero di analisti 12/31/2026 14 -248 -236 -219 12 12/31/2025 0 -226 -210 -179 14 12/31/2024 0 -194 -218 -153 15 9/30/2024 1 -182 -143 -140 N/A 6/30/2024 0 -168 -146 -144 N/A 3/31/2024 0 -160 -137 -135 N/A 12/31/2023 0 -153 -127 -125 N/A 9/30/2023 0 -142 -123 -120 N/A 6/30/2023 N/A -127 -113 -111 N/A 3/31/2023 N/A -116 -105 -103 N/A 12/31/2022 N/A -105 -71 -70 N/A 9/30/2022 20 -82 -69 -68 N/A 6/30/2022 20 -79 -59 -58 N/A 3/31/2022 20 -67 -54 -53 N/A 12/31/2021 20 -59 -63 -62 N/A 9/30/2021 0 -61 -51 -51 N/A 6/30/2021 0 -53 -48 -47 N/A 3/31/2021 N/A -49 -40 -39 N/A 12/31/2020 N/A -45 -37 -37 N/A 9/30/2020 3 -39 -35 -34 N/A 6/30/2020 5 -31 -27 -26 N/A 3/31/2020 8 -23 -22 -22 N/A 12/31/2019 10 -14 -16 -16 N/A 12/31/2018 10 -2 7 7 N/A
Mostra di più
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di KROS ( 79.7% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di KROS ( 79.7% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di KROS è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
